Dr. Kim Papp

Dermatologist, Kitchener, ON

Dr. Kim Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American Academy of Dermatology. The Waterloo, Ontario, Canada based dermatologist has over 25 years’ experience as a Principal Investigator, and has conducted over 170 psoriasis studies in which he closely supervised and assessed over 2750 subjects. Dr. Papp is an internationally renowned Key Opinion Leader in clinical research who conducts clinical trials on a wide range of dermatological disorders.

Dr. Papp, with the support of Probity Medical Research, an organization for which he serves as Founder and President, has earned the distinction of top enrolling investigator in over 70 international dermatology studies.

Dr. Papp has conducted early through late phase psoriasis studies, and has been instrumental in the investigation and development of the following compounds: adalimumab (Humira®), AIN457, alefacept, AMG714, AMG827, apremilast (CC-10004), BIRB 796 BS, BIRT 2584XX, BMS-582949, briakinumab (ABT-874), CD 2027, clobex, CP-690,550, CRx-140, cyclosporine, dovobet, dovonex, efalizumab, etanercept, golimumab, ILV094, infliximab, KH 1650, MEDI-507, MEDI-545, methotrexate, onercept, recombinant human interleukin eleven (rhIL-11), roziglitazone maleate, RWJ-445380,tacrolimus, tazorac, tofacitinib (CP-690, 550), ustekinumab (CNTO1275), volclosporine (ISA247)

K. Papp Clinical Research, like many high-enrolling research sites, has had routine inspections by the Food and Drug Administration, Health Canada, and the European Medicines Agency. Dr. Papp’s clinic has the unique distinction of producing no significant findings; the FDA’s Form 483—a standard document issued to non-compliant research centres—has never been issued to K. Papp Clinical Research.

Dr. Papp has acted as consultant and/or advisor to over 40 pharmaceutical companies on the development of dermatological compounds. He is instrumental in improving and refining study designs, and serves on a number of Steering Committees and Advisory Boards tasked with developing effective and efficient strategies for the timely development of new treatments. An author on over 275 publications, and a highly sought-after speaker known for delivering engaging, thought-provoking and accessible presentations, Dr. Papp is held in the highest esteem by the academic and medical communities.